Suvretta Capital Management’s Solid Biosciences SLDB Stock Holding History

Suvretta Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-40,000	Closed	-$4.2M	–	105
2022 Q3	$4.2M	Sell	40,000 -297,814	-88%	-$3M	0.17%	57
2022 Q2	$3.12M	Sell	337,814 -143,843	-30%	-$1.49M	0.12%	70
2022 Q1	$8.67M	Buy	481,657 +62,511	+15%	+$1.1M	0.26%	55
2021 Q4	$11M	Buy	419,146 +20,866	+5%	+$638K	0.21%	60
2021 Q3	$14.3M	Hold	398,280	–	–	0.24%	55
2021 Q2	$21.9M	Hold	398,280	–	–	0.33%	60
2021 Q1	$33M	Buy	398,280 +128,010	+47%	+$14.2M	0.49%	47
2020 Q4	$30.7M	Buy	+270,270	New	+$17.1M	0.44%	47

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Suvretta Capital Management's SLDB Position: Q4 2022 in Review

Suvretta Capital Management sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 40,000 shares — an estimated $4.2M sold.

Suvretta Capital Management first reported a position in SLDB in Q4 2020 and held it in 8 quarters. The position peaked at $33M in Q1 2021. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

Suvretta Capital Management reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
Suvretta Capital Management sold 40,000 Solid Biosciences shares in Q4 2022, an estimated $4.2M.
Suvretta Capital Management first reported a position in Solid Biosciences in Q4 2020 and held it in 8 quarters.
Suvretta Capital Management's Solid Biosciences position peaked at $33M in Q1 2021.
35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.